Human Tumor-derived Exosomes (TEX) Regulate Treg Functions Via Cell Surface Signaling Rather Than Uptake Mechanisms
Overview
Authors
Affiliations
Tumor-derived exosomes (TEX) are ubiquitously present in the tumor microenvironment and plasma of cancer patients. TEX carry a cargo of multiple stimulatory and inhibitory molecules and deliver them to recipient cells, serving as a communication network for the tumor. The mechanisms TEX use for delivering messages to recipient cells were evaluated using PKH26-labeled TEX produced by cultured human tumor cells, exosomes produced by dendritic cells-derived exosomes (DEX), or exosomes isolated from plasma of cancer patients (EXO). Human T-cell subsets, B cells, NK cells, and monocytes were co-incubated with TEX, DEX, or EXO and binding or internalization of labeled vesicles was evaluated by confocal microscopy and/or Amnis-based flow cytometry. Vesicle-induced Ca influx in recipient T cells was monitored, and TEX-induced inosine production in Treg was determined by mass spectrometry. In contrast to B cells, NK cells or monocytes, conventional T cells did not internalize labeled vesicles. Minimal exosome uptake was only evident in Treg following prolonged co-incubation with TEX. All exosomes induced Ca influx in T cells, with TEX and EXO isolated from cancer patients' plasma delivering the strongest, sustained signaling to Treg. Such sustained signaling resulted in the significant upregulation of the conversion of extracellular ATP to inosine (adenosine metabolite) by Treg, suggesting that TEX signaling could have functional consequences in these recipient cells. Thus, modulation of Treg suppressor functions by TEX is mediated by mechanisms dependent on cell surface signaling and does not require TEX internalization by recipient cells.
A GD (Gamma-Delta) type of cancel culture.
Lim W, Iyer N Immunooncol Technol. 2024; 24:100740.
PMID: 39717204 PMC: 11664092. DOI: 10.1016/j.iotech.2024.100740.
Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy.
Yang M, Zhou J, Lu L, Deng D, Huang J, Tang Z Exploration (Beijing). 2024; 4(6):20230171.
PMID: 39713208 PMC: 11655317. DOI: 10.1002/EXP.20230171.
Whiteside T J Cancer Immunol (Wilmington). 2024; 6(4):162-168.
PMID: 39634254 PMC: 11616454. DOI: 10.33696/cancerimmunol.6.097.
Extracellular vesicle-mediated communication between CD8 cytotoxic T cells and tumor cells.
Huang Z, Liu X, Guo Q, Zhou Y, Shi L, Cai Q Front Immunol. 2024; 15:1376962.
PMID: 38562940 PMC: 10982391. DOI: 10.3389/fimmu.2024.1376962.
Exosomes-Promising Carriers for Regulatory Therapy in Oncology.
Jozwicka T, Erdmanska P, Stachowicz-Karpinska A, Olkiewicz M, Jozwicki W Cancers (Basel). 2024; 16(5).
PMID: 38473285 PMC: 10931160. DOI: 10.3390/cancers16050923.